<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/37D1AD63-EAF7-4241-A91B-F13EC15C7BA6"><gtr:id>37D1AD63-EAF7-4241-A91B-F13EC15C7BA6</gtr:id><gtr:name>King?s Health Partners</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5A51966A-5E02-4F70-A0D3-68077A2C4C03"><gtr:id>5A51966A-5E02-4F70-A0D3-68077A2C4C03</gtr:id><gtr:name>Merck &amp; Co. Inc. (MSD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Cardiovascular</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/37D1AD63-EAF7-4241-A91B-F13EC15C7BA6"><gtr:id>37D1AD63-EAF7-4241-A91B-F13EC15C7BA6</gtr:id><gtr:name>King?s Health Partners</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5A51966A-5E02-4F70-A0D3-68077A2C4C03"><gtr:id>5A51966A-5E02-4F70-A0D3-68077A2C4C03</gtr:id><gtr:name>Merck &amp; Co. Inc. (MSD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EA8C975A-0C94-4BCE-82DA-19D4FA26832D"><gtr:id>EA8C975A-0C94-4BCE-82DA-19D4FA26832D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Marber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802033"><gtr:id>361A9E37-04CF-4172-9448-BFDCD04A45CE</gtr:id><gtr:title>The role of individual isoforms of p38 mitogen-activated protein kinase in myocardial infarction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802033</gtr:grantReference><gtr:abstractText>Blockage of a coronary artery causes a heart attack. This decribes the symptoms caused by the death of the heart muscle downstream of the blockage. We are intersted in preventing the death of this muscle by studying the role of proteins known as p38 mitogen-activated protein kinases. These proteins aggravate muscle death and also cause on-going heart damage that can lead to heart failure.</gtr:abstractText><gtr:technicalSummary>Although there is general agreement that p38-Mitogen-Activated Protein Kinases (p38-MAPKs) play a crucial role in preconditioning, myocardial infarction and heart failure the contribution of individual p38 isoforms is either unknown or controversial. There are four p38-MAPK isoforms, alpha, beta, gamma and delta, and all have been reported to be expressed in the heart. However, the most commonly used readout of p38-MAPK activation, an immunoreactive dual phosphorylation motif within the activation loop, is common to all isotopes. Similarly, the pharmacological inhibitors used to infer involvement show poor selectivity for p38-MAPKs over other kinases or for one p38 MAPK isoform over another. The interpretation of any observations made with these inhibitors is further compounded by the fact that the alpha and beta isoforms, most sensitive to the commonly used pharmacological inhibitors, are thought to have opposing physiological roles. Finally, there is no small molecule that selectively inhibits either the gamma or delta isoforms. In combination these limitations have made it difficult to ascribe an observed physiological effect to a particular p38 isoform. 
We propose to determine the contribution of individual p38 isoforms to preconditioning, myocardial infarction and post-infarction remodelling using our established murine models together with targeted mouse lines. The individual contribution of the beta, gamma and delta isoforms will be determined using the relevant ?knock out? line. The contribution of the alpha and beta isoforms will be determined using a chemical genetic approach utilising an allele-specific mutation that results in the substitution of a threonine residue critical to the binding of pharmacological inhibitors but not of ATP. 
Our findings may lead to a greater understanding of the therapeutic benefits of ?blanket? p38-MAPK inhibition and to the substrates that mediate specific physiological effects. Such information may ultimately be used to avoid the toxicity that has curtailed a number of clinical trial programmes of p38 MAPK inhibition.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-18</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>627561</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King?s Health Partners</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>use of MKK3 targetted mice</gtr:description><gtr:id>F59B67F5-7F6B-4320-A5E7-13F10420229A</gtr:id><gtr:impact>Pulm Pharmacol Ther. 2014 Apr;27(2):156-63. A role for mitogen kinase kinase 3 in pulmonary inflammation validated from a proteomic approach.
Holand T1, Riffo-Vasquez Y1, Spina D1, O'Connor B1, Woisin F1, Sand C2, Marber M3, Bacon KB4, Rohlff C5, Page CP6.</gtr:impact><gtr:partnerContribution>Research in an asthma model</gtr:partnerContribution><gtr:piContribution>Provision of targeted mouse line</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Discovery Partnership With Academia</gtr:description><gtr:id>95DB2E87-A4DC-474D-B745-09F7881D938B</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:partnerContribution>Provision of novel high through put screen</gtr:partnerContribution><gtr:piContribution>Provision of knowledge, X-ray structures, recombinant proteins and orthogonal screens</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck &amp; Co. Inc. (MSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Use of drug resistant knock-in mice</gtr:description><gtr:id>5E75AB5B-EBC1-4795-8190-D169DBD4F56C</gtr:id><gtr:impact>Collaborator is Stephen O'Keefe who appears on following publications
J Mol Cell Cardiol. 2010 Jun;48(6):1324-8.
J Biol Chem. 2010 Jan 29;285(5):2968-75.</gtr:impact><gtr:partnerContribution>Provision of powerful mouse line for research. We now act as distributor of line since Merck have reopiganised their research and no longer have an interst in p38 MAPK.</gtr:partnerContribution><gtr:piContribution>Characterisation of mouse line created byMerck</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to prospective undergraduate students</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D2B6E2D0-478A-427F-8365-3DA151EBF768</gtr:id><gtr:impact>Approximately 100 students attended a talk designed to attract local students from poorly performning schools and low socioeconomic backgrounds into our extended medical degree programme as part of our attempts to widening access to medicine.

Lots of questions from the audience. Not sure how many ended up applying!</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Translational Award</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>TG/15/1/31518</gtr:fundingRef><gtr:id>1C452D4F-0EB6-46E5-A3E3-6781EE82EAA6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEE37DF3-23F2-4A80-B608-A4D06771C978"><gtr:id>FEE37DF3-23F2-4A80-B608-A4D06771C978</gtr:id><gtr:title>Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point.</gtr:title><gtr:parentPublicationTitle>Drug discovery today. Disease mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99cf258918bd7b3866fa8aeba91e35b3"><gtr:id>99cf258918bd7b3866fa8aeba91e35b3</gtr:id><gtr:otherNames>Marber MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-6765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B0343B5-5729-4E0A-B14E-5EE9D69CE5C8"><gtr:id>8B0343B5-5729-4E0A-B14E-5EE9D69CE5C8</gtr:id><gtr:title>Troponins and other biomarkers in the early diagnosis of acute myocardial infarction.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eba6290ba44d76912d2a786e20bdcc85"><gtr:id>eba6290ba44d76912d2a786e20bdcc85</gtr:id><gtr:otherNames>Maznyczka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD5996FB-0696-48F9-929A-59E8764AC920"><gtr:id>FD5996FB-0696-48F9-929A-59E8764AC920</gtr:id><gtr:title>A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8dbe5f527728b7865ff5c8c33acffc71"><gtr:id>8dbe5f527728b7865ff5c8c33acffc71</gtr:id><gtr:otherNames>Kumphune S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEA6C58E-2AF9-4E07-ABB5-3F875DF036A4"><gtr:id>FEA6C58E-2AF9-4E07-ABB5-3F875DF036A4</gtr:id><gtr:title>The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3f6de537b84b1dfcd7a7ec5228d6038"><gtr:id>b3f6de537b84b1dfcd7a7ec5228d6038</gtr:id><gtr:otherNames>Sicard P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F065B39-2152-4C10-BE85-F36EB97CBD91"><gtr:id>0F065B39-2152-4C10-BE85-F36EB97CBD91</gtr:id><gtr:title>p38 MAPK in cardioprotection - are we there yet?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c7ec72e6fdcaebf866bd9a50224ebac"><gtr:id>6c7ec72e6fdcaebf866bd9a50224ebac</gtr:id><gtr:otherNames>Martin ED</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3831B36-40BF-4E9F-A5EE-D493B0B1DEE1"><gtr:id>C3831B36-40BF-4E9F-A5EE-D493B0B1DEE1</gtr:id><gtr:title>Advancements in pressure-volume catheter technology - stress remodelling after infarction.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7760d349b99ceb56061f5108c2755fe"><gtr:id>e7760d349b99ceb56061f5108c2755fe</gtr:id><gtr:otherNames>Clark JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A56DCBF5-CF99-448D-8863-51EC2AFF0EEA"><gtr:id>A56DCBF5-CF99-448D-8863-51EC2AFF0EEA</gtr:id><gtr:title>Mechanism and consequence of the autoactivation of p38a mitogen-activated protein kinase promoted by TAB1.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97e4bde5456def0b4abfa1a8d83a5996"><gtr:id>97e4bde5456def0b4abfa1a8d83a5996</gtr:id><gtr:otherNames>De Nicola GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3061DEA-0121-4177-84B1-E1CD6FF22FE7"><gtr:id>E3061DEA-0121-4177-84B1-E1CD6FF22FE7</gtr:id><gtr:title>The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C.</gtr:title><gtr:parentPublicationTitle>Translational research : the journal of laboratory and clinical medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4f804f322605c774308bae4229626320"><gtr:id>4f804f322605c774308bae4229626320</gtr:id><gtr:otherNames>Marjot J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1878-1810</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9C9E185-0D28-434E-983F-B6D621A3E4D9"><gtr:id>E9C9E185-0D28-434E-983F-B6D621A3E4D9</gtr:id><gtr:title>Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury.</gtr:title><gtr:parentPublicationTitle>Basic research in cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dd01bba696a4b07434703b50889b1bd"><gtr:id>3dd01bba696a4b07434703b50889b1bd</gtr:id><gtr:otherNames>Baker JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8428</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44F76974-7AED-491C-85C1-294059DB4627"><gtr:id>44F76974-7AED-491C-85C1-294059DB4627</gtr:id><gtr:title>Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.</gtr:title><gtr:parentPublicationTitle>JACC. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/331f0e6bf5000a1ee15290d747ada88b"><gtr:id>331f0e6bf5000a1ee15290d747ada88b</gtr:id><gtr:otherNames>Elkhawad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1876-7591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25B8AA8D-066D-4716-B585-44E2F4561402"><gtr:id>25B8AA8D-066D-4716-B585-44E2F4561402</gtr:id><gtr:title>New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92427b4ab1bba32fda00e3d07383c847"><gtr:id>92427b4ab1bba32fda00e3d07383c847</gtr:id><gtr:otherNames>Denise Martin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A1F93A3-4A76-48E9-A487-630E082F187C"><gtr:id>7A1F93A3-4A76-48E9-A487-630E082F187C</gtr:id><gtr:title>Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73bf09b5f239ca9adf1ea0c9bc4b892e"><gtr:id>73bf09b5f239ca9adf1ea0c9bc4b892e</gtr:id><gtr:otherNames>Newby LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21357ABC-EA2A-401C-B010-FF2B388AFA5F"><gtr:id>21357ABC-EA2A-401C-B010-FF2B388AFA5F</gtr:id><gtr:title>Will o' the WISP1: a novel mediator of Ang-II induced cardiomyocyte hypertrophy.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c7ec72e6fdcaebf866bd9a50224ebac"><gtr:id>6c7ec72e6fdcaebf866bd9a50224ebac</gtr:id><gtr:otherNames>Martin ED</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802033</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>